The cost-effectiveness component of the 18-month CATIE trial of schizophrenia pharmacotherapy (n = 1460) showed that the first-generation antipsychotic perphenazine was US$300-600 per month less expensive than each of four second-generation antipsychotics, and no less effective across multiple measures. We consider whether or not each of eight potential methodological limitations could weaken this conclusion: follow-up rates, study duration, sample characteristics, the choice of outcome measures, exclusion of patients with tardive dyskinesia from assignment to perphenazine, choice of study drugs and doses, reliance on intention-to-treat analysis, and differences in prestudy treatment. We conclude that results of CATIE are robust to these limitations. Perphenazine seems to have been a more representative choice for first-generation antipsychotic comparison treatment than haloperidol.
Second-generation antipsychotics
Reviewing the cost-effectiveness component of the CATIE trial
Rosenheck, R., Swartz, M., McEvoy, J., Stroup, T. S., Davis, S., Keefe, R. S., Hsiao, J., & Lieberman, J. (2007). Second-generation antipsychotics: Reviewing the cost-effectiveness component of the CATIE trial. Expert Review of Pharmacoeconomics & Outcomes Research, 7(2), 103-111. https://doi.org/10.1586/14737167.7.2.103
Abstract
Publications Info
To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.
Meet the Experts
View All ExpertsRecent Publications
Article
The use of patient experience feedback in rehabilitation quality improvement and codesign activities
Article
Protection of forest ecosystems in the eastern United States from elevated atmospheric deposition of sulfur and nitrogen
Article
SPTSSA variants alter sphingolipid synthesis and cause a complex hereditary spastic paraplegia
OCCASIONAL PAPER